Previous 10 | Next 10 |
2023-11-09 12:18:43 ET More on Ikena Oncology Ikena Oncology a new buy at Wedbush on cancer asset with new target Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology ...
2023-11-09 10:00:37 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions Encouraging signs of clinical activity and tumor shrinkage in multiple patients with...
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor confer...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Ikena Oncology Inc. (IKNA) is expected to report $-0.44 for Q3 2023
2023-09-22 14:28:36 ET More on Ikena Oncology Ikena falls on acquisition of Pionyr in all-stock deal Seeking Alpha’s Quant Rating on Ikena Oncology Historical earnings data for Ikena Oncology Financial information for Ikena Oncology ...
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor confere...
2023-08-21 11:52:45 ET More on Health Care Select Sector SPDR XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air Goldman add...
2023-08-10 10:26:07 ET Ikena Oncology press release ( NASDAQ: IKNA ): Q2 GAAP EPS of -$0.44. Revenue of $2M. For further details see: Ikena Oncology GAAP EPS of -$0.44, revenue of $2M
News, Short Squeeze, Breakout and More Instantly...
Ikena Oncology Inc. Company Name:
IKNA Stock Symbol:
NASDAQ Market:
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, In...
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")), a targeted oncology company forging new ter...
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2...